Neumora Therapeutics Inc. (NMRA)
NMRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NMRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001885522 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $116.8M cash; operating cash flow -$45.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 187,895,912 (2026-08-10); 161,945,427 a year earlier; 152,703,316 three years earlier. | Cover page 2026-08-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-10-30 |
| Auditor | Ernst & Young LLP, San Jose, California, United States | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5.0M, sold $1.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$43.1M | -$39.5M | $116.8M | $52.9M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$53.5M | -$46.4M | $147.1M | $53.0M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$59.5M | -$48.0M | $182.5M | $54.5M | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$56.8M | -$46.6M | $129.1M | $19.6M | Needs four quarters | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$52.7M | -$52.4M | $124.5M | $19.5M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$68.0M | -$59.4M | $126.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$58.8M | -$50.3M | $142.1M | $0 | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$72.5M | -$33.5M | $275.7M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-03-03 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 259 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.7% |
| 1 month | +15.9% |
| 3 months | -75.2% |
| Year to date | -76.0% |
| 1 year | -84.1% |
| From 52-week high | -88.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.3336 | -4.47% | $76.0M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| CHRS | Coherus Oncology Inc. | $0.5059 | -3.73% | $78.2M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier